{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:37:51Z","timestamp":1794717471061,"version":"4.9.1"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T00:00:00Z","timestamp":1406073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Aarhus University"},{"DOI":"10.13039\/501100004046","name":"Karen Elise Jensen Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004046","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005747","name":"A. P. M\u00f8ller and Chastine Mc-Kinney M\u00f8ller Foundation for General Purposes","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005747","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Foundation of Eva and Henry Fraenkel"},{"name":"Mimi & Victor Larsens Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Clinical trials (CTs) are needed to improve the outcome for peripheral T\u2010cell lymphomas (PTCL), and accrual into CTs is one of the main recommendations in international treatment guidelines. The use of risk\u2010adapted strategies has been suggested as a way to optimize treatment outcome in PTCL. The aim of the present study was to evaluate CT eligibility and selected prognostic indices in a population\u2010based PTCL cohort of 481 PTCL patients identified from the Danish Lymphoma Registry in the period 2000\u20132010. According to five predefined parameters (age, performance status, P\u2010creatinine, P\u2010ALAT and measurable tumour lesion), patients were subdivided into four groups: \u2018younger fit\u2019, \u2018elderly fit\u2019, \u2018frail\u2019 and \u2018not CT eligible\u2019. International prognostic index (IPI), prognostic index for T\u2010cell lymphoma (PIT) and anaplastic lymphoma kinase (ALK) protein expression were tested at subtype\u2010specific level. Overall, 41% of the patients were considered eligible for interventional CTs implicating curatively intended multiagent chemotherapy, including, if considered appropriate, consolidating stem cell transplantation (SCT), as part of the upfront management strategy. Moreover, 28% was elderly fit and eligible for interventional CT, including those with SCT as part of the trial design. Approximately 7% were defined as \u2018too frail\u2019 for aggressive treatment schedules, whereas 24% were deemed not to be eligible for any CT. Both overall and progression\u2010free survivals were effectively predicted by IPI and PIT (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009\n                    <jats:italic>0<\/jats:italic>\n                    .\n                    <jats:italic>001<\/jats:italic>\n                    ). ALK\u2010positive anaplastic large cell lymphoma patients were significantly younger (median age 40 vs. 62,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009\n                    <jats:italic>0<\/jats:italic>\n                    .\n                    <jats:italic>001<\/jats:italic>\n                    ) and had a better outcome than their ALK\u2010negative counterparts (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009\n                    <jats:italic>0<\/jats:italic>\n                    .\n                    <jats:italic>001<\/jats:italic>\n                    ). However, ALK expression lost its prognostic significance when adjusting for age. In a population\u2010based cohort of adult Caucasian PTCL patients, approximately half were eligible for multiagent chemotherapy with or without consolidating SCT. Both IPI and PIT are useful prognostic indices in all \u2018primary nodal\u2019 PTCL entities. The prognostic value of ALK protein expression in anaplastic large cell lymphoma is significantly downsized when adjusting for age. Copyright \u00a9 2014 John Wiley &amp; Sons, Ltd.\n                  <\/jats:p>","DOI":"10.1002\/hon.2153","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T01:21:04Z","timestamp":1406078464000},"page":"120-128","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of clinical trial eligibility and prognostic indices in a population\u2010based cohort of systemic peripheral T\u2010cell lymphomas from the Danish Lymphoma Registry"],"prefix":"10.1002","volume":"33","author":[{"given":"Martin Bjerregaard","family":"Pedersen","sequence":"first","affiliation":[{"name":"Department of Hematology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Jacques","family":"Hamilton\u2010Dutoit","sequence":"additional","affiliation":[{"name":"Institute of Pathology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knud","family":"Bendix","sequence":"additional","affiliation":[{"name":"Institute of Pathology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Boe","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Department of Pathology Odense University Hospital  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"N\u00f8rgaard","sequence":"additional","affiliation":[{"name":"Department of Pathology Herlev Hospital  Herlev Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preben","family":"Johansen","sequence":"additional","affiliation":[{"name":"Department of Pathology Aalborg University Hospital  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Ralfkiaer","sequence":"additional","affiliation":[{"name":"Department of Pathology Copenhagen University Hospital  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter De Nully","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Hematology Copenhagen University Hospital  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Boye","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Hematology Herlev Hospital  Herlev Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Amdi","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Hematology Odense University Hospital  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Madsen","sequence":"additional","affiliation":[{"name":"Department of Hematology Aalborg University Hospital  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sch\u00f6llkopf","sequence":"additional","affiliation":[{"name":"Department of Hematology Roskilde Hospital  Roskilde Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"d'Amore","sequence":"additional","affiliation":[{"name":"Department of Hematology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,7,23]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"WPG. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Swerdlow S","year":"2008"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-010-0125-0"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/623924"},{"issue":"1","key":"e_1_2_8_7_1","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht C","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-013-0232-x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4870"},{"issue":"21","key":"e_1_2_8_11_1","first-page":"57","article-title":"First interim efficacy and safety analysis of an international phase III randomized trial in newly diagnosed systemic peripheral T\u2010cell lymphoma treated with chemotherapy with or without alemtuzumab and consolidated by high dose therapy","volume":"120","author":"d'Amore F","year":"2012","journal-title":"ASH Annu Meet Abstr"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl466"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705752"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.12.6219"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.09.014"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.11.010"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.02.008"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2011.009"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2012.2143"},{"key":"e_1_2_8_20_1","unstructured":"National Comprehensive Cancer Network.NCCN guidelines for professionals.2014."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0596"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.050"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404822"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.017.:S15\u2010S17"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.0188"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3080"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1685-5"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00856.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn022"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq359"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.11.3913"},{"issue":"8","key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood.V93.8.2688","article-title":"Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma","volume":"93","author":"Berge RL","year":"1999","journal-title":"Blood"},{"issue":"8","key":"e_1_2_8_37_1","first-page":"2697","article-title":"ALK\u2009+\u2009lymphoma: clinico\u2010pathological findings and outcome","volume":"93","author":"Falini B","year":"1999","journal-title":"Blood"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2345"},{"issue":"9","key":"e_1_2_8_39_1","first-page":"2993","article-title":"Prognostic significance of CD56 expression for ALK\u2010positive and ALK\u2010negative anaplastic large\u2010cell lymphoma of T\/null cell phenotype","volume":"96","author":"Suzuki R","year":"2000","journal-title":"Blood"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2153","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:35:17Z","timestamp":1696379717000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,23]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1002\/hon.2153"],"URL":"https:\/\/doi.org\/10.1002\/hon.2153","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,23]]}}}